🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — April 22, 2026

The April 22, 2026, US SEC filings digest reveals a quiet trading day dominated by 30+ 13F-HR reports from institutional managers, signaling sustained conviction in broad-market ETFs (Vanguard, Dimensional, iShares), tech giants (NVDA, AAPL, MSFT averaging 20-30% portfolio weights across filers), and value/small-cap tilts, with total AUM exceeding $10B in disclosed holdings. Q1 2026 earnings from Otis, Elevance, Vertiv, and Monarch highlight divergent industrials/healthcare trends: aggregate revenue growth of +11.6% YoY (Vertiv +30%, Otis +6%, Monarch +8.9%, Elevance +1.5%) but mixed margins (Vertiv +430bps outlier vs Otis -130bps, Elevance operating gain -34%). Positive catalysts include HIVE's $100M notes upsizing for GPU expansion, National Healthcare's $560M accretive M&A, Kyverna's positive trial data, and First Northern's Nasdaq uplisting; offsets include Otis China weakness, Gaotu persistent losses, Oak Woods SPAC merger termination, and CDT dilution risks. Capital allocation remains shareholder-friendly with $400M Otis buybacks, Monarch's $17.6M repurchases + $0.30 div, Elevance's $5.6B auth remaining + $1.72 div. Forward guidance leans constructive (Vertiv/Elevance raises), building a catalyst calendar around Q2 earnings, June dividends/meetings, and Q3 M&A closes. Portfolio implications: Overweight data center/AI enablers (Vertiv/HIVE) and healthcare operators amid resilient service growth; monitor industrials for China exposure.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 22, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (despite heavy financials/banks skew), Q1 2026 bank results dominate with mixed outcomes: 5/7 banks showed reported net income declines QoQ (avg -20%) due to merger costs/MTM losses but adjusted EPS often up YoY (e.g., First Merchants +9.6%, Pinnacle +26%), loans/deposits surged post-M&A (Pinnacle +118%/+111% LQ). Consumer discretionary pure-plays like Ulta Beauty (DEF 14A/DEFA14A) emphasize governance upgrades ahead of June 9 AGM, Winmark AGM >97% approvals. 30+ 13F-HRs reveal institutional conviction in tech/consumer names (Apple top in 15/30, avg $5-12M positions; Walmart heavy in MFA/Churchill), gold ETFs (Fulcrum/SPDR top), and broad ETFs, with no major shifts. Forward guidance bullish from Boston Scientific (FY26 organic sales 6.5-8%, Q2 5-7%). Capital allocation resilient: dividends maintained (FS Bancorp 53rd consecutive $0.29, Bankwell $0.20), Stifel 3:2 split. Risks include NIM compression (Bankwell -12bps), rising NPLs (Pinnacle 0.58%, Bankwell 0.66%), related-party debt (FreeCast $3.4M). Implications: M&A-driven growth but integration drags; monitor bank credit quality and Ulta vote outcomes for sector sentiment.

3 high priority 47 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 22, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, Q1 2026 earnings show robust revenue growth in select areas like med devices (Boston Scientific +11.6% YoY) and financial services adjacent to healthcare (Stifel +18% YoY, CACI +8.5% YoY), but mixed results with pressures on margins (Bankwell NIM -12bps), operating gains (Elevance -34.2% YoY), and memberships (Medicare Advantage -15.8% YoY). Healthcare-specific filings highlight positive organizational shifts at Amgen for AI-driven R&D and non-dilutive funding at TuHURA extending runway to 2028, alongside biotech events like Spruce's public offering. Over 25 13F-HR filings from managers like Pinnacle Associates, AtlasMark, and Parcion reveal extreme concentration in tech megacaps (Nvidia top in 10+ portfolios, e.g., Ketron $124M) and ETFs, with minimal healthcare exposure (e.g., Biltmore $25.6M Health Care ETF outlier), signaling institutional derisking from sector amid volatility. Capital allocation trends favor dividends (Elevance $1.72 Q2, Civista +6% to $0.18) and buybacks (News Corp $1B program), while M&A integration challenges post-deals (Pinnacle loans +118% LQ but EPS -50% YoY) dominate financials. Forward guidance largely raised (CACI rev to $9.5-9.6B, Elevance EPS $26.75+), building a catalyst calendar into Q2-Q3 2026. Portfolio-level, 7/12 earnings reporters posted YoY revenue growth averaging +20%, but 5 showed margin/NIM compression averaging -20bps, implying selective opportunities in growth outperformers.

6 high priority 44 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 22, 2026

Across 50 DEF 14A proxy statements filed on April 22, 2026, for US SEC-listed firms, overarching themes include routine approvals for director elections, auditor ratifications, and advisory say-on-pay votes ahead of virtual AGMs clustered in May-June 2026, with 80% recommending annual pay frequency. Where enriched data available (15/50 filings), period-over-period trends show robust revenue growth averaging +15% YoY (e.g., Veracyte +16%, LegalZoom +11%, Oscar Health 41% CAGR 2023-2025), margin expansions (LegalZoom adj EBITDA 23%), and deposit/asset growth (Western Alliance +16.3% deposits YoY), though outliers like SAIC (-3% revenue YoY) highlight sector headwinds. Governance enhancements dominate (e.g., board declassifications in Ulta, Veracyte; independent chairs in GXO), alongside equity-heavy comp (PSUs tied to revenue/TSR/rTSR in Resideo, Pulmonx, LegalZoom) aligning pay with performance. Capital allocation favors buybacks ($422M Western Alliance, $375M Keros) over dividends, signaling confidence; leadership transitions (e.g., Pulmonx CEO/CFO changes with severance/sign-ons) mix bullish growth with dilution risks from equity plan expansions (Cerus +10M shares). Portfolio-level patterns reveal biotech (20+ firms) vulnerability to program halts (Keros cibotercept discontinued) vs. tech/fintech outperformance (Robinhood assets doubled). Market implications: High say-on-pay approval potential boosts sentiment, but watch dilution and reverse splits (Offerpad 1:5-50, DocGo 1:5-10) for pressure.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 22, 2026

The IPO Pipeline stream reveals a diverse set of capital market activities on April 22, 2026, including a fresh SPAC IPO by BurTech Acquisition Corp II targeting $100M, biopharma consolidation via Gazelle Parent's S-4 mergers requiring $350M cash infusion, a regional bank merger between Arrow Financial and Adirondack Bancorp, and CytoDyn's equity shelf registration amid ongoing balance sheet updates through February 2026. Absent explicit YoY/QoQ financial trends across filings, biopharmas highlight persistent historical losses and future unprofitability, contrasting BurTech's clean $100M trust deposit structure. Positive sentiment for BurTech signals SPAC market revival, while mixed/neutral tones for others underscore execution risks in mergers and dilutions. Portfolio-level patterns show heavy reliance on M&A/de-SPAC for biotech/fintech growth, with no dividend/buyback activity noted. Critical implications include near-term Nasdaq listings and stockholder votes as catalysts, favoring tactical plays in SPACs over risky biopharma combos.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 22, 2026

The 50 filings reveal a surge in SPAC activity with 7 new S-1/S-1A registrations (BurTech, RRE, ARC, etc.) signaling renewed blank-check IPO momentum amid favorable market conditions, alongside robust M&A in pharma (Amneal's $1.1B Kashiv deal) and healthcare real estate (NHC's $560M acquisition). Indian filings dominate insolvencies and open offers (9 cases including Kwality Walls 26% open offer at ₹21.33, AAA Tech 26% at ₹101), highlighting distress in real estate/infra but opportunistic takeovers. US period-over-period trends show revenue growth averaging +15% YoY across reporting firms (Gaotu +35%, GE Vernova +16%, Viomi +14.6%, LegalZoom +11%), but mixed profitability with op income declines (Viomi -17.8%) and net losses (Gaotu -$46M). Guidance raises (Amneal EBITDA to $740-770M, +3%) and capital returns (LegalZoom $80M cashback, GE Vernova $1.3B buybacks) bolster bullish signals, while regulatory penalties (Birla ₹4.6Cr) and SPAC terminations (Oak Woods, PlusAI) flag risks. Portfolio-level: Pharma/healthcare outperforms with synergies ($400-500M Amneal), contrasted by flat/declining metrics in Chinese tech (Yalla rev +0.7%). Critical implications: Monitor May-June AGMs/proxies for governance votes and Q4FY26 earnings boards (Bondada Apr27, Kajaria Apr30).

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 22, 2026

Across 36 Q1 2026 financial filings (mostly 10-Qs, some 10-Ks), revenue growth averaged ~10-15% YoY in high performers like GE Vernova (+16%), Vertiv (+30%), EQT (+94%), and Intuitive Surgical (+23%), but was mixed with declines in homebuilding (Taylor Morrison -27%), beverages (Constellation -10%), and healthcare services (Community Health -6%). Profitability showed stark contrasts: blowout net income surges (GE Vernova to $4.7B, EQT +515%) versus widening losses (Reborn Coffee -87%, KKR RE to $57M loss). Capital allocation leaned heavily toward aggressive buybacks totaling billions (e.g., Calix $172M, J&J $4B, Intuitive $1.1B) and acquisitions (GEV $4.9B, Boeing Spirit $8.4B, Wabtec $1.1B), signaling management conviction amid cash generation improvements in 20+ firms (e.g., United Airlines +29% op cash). Margin trends were pressured in 12/36 companies (avg -50-200bps compression from costs/investments), but industrials/energy outperformed with expansion. REITs faced credit/impairment hits (KKR +196% provisions), while airlines/industrials showed resilience. Portfolio implication: overweight growth industrials/energy on buybacks/M&A; trim cyclical decliners like housing/REITs ahead of potential slowdowns.

36 high priority 36 total filings
· daily

US SEC Trading Suspension Halt Orders — April 22, 2026

A surge of 8 small-cap companies across energy, biotech/pharma, technology, and real estate sectors received noncompliance notices from NYSE American (3) and Nasdaq (5) between April 16-20, 2026, primarily for failing to file 10-Ks for FY ended Dec 31, 2025, signaling systemic audit delays and financial reporting weaknesses among micro-caps. 7/8 filings cite late 10-Ks (Form 12b-25 filed March/April 2026), with one (Tevogen) failing market value rules ($50M MVLS, $15M MVPHS) and Vivos reporting negative equity of -$1.55M despite Q1 2026 $6.8M raise ($4.6M warrants + $2.25M placement). Sentiments are negative across 7/8 (mixed for Vivos), all 9/10 materiality, with cure periods clustered around October 12-15, 2026, after initial 60-180 day plans. No YoY/QoQ financial trends or insider activity reported, but operational highlights include EON's 1,000+ bopd from 750 Permian wells and La Rosa's Europe expansion. Delisting risks loom without assurances of compliance, pressuring listings and liquidity; Apimeds faces active trading halt since April 2. Portfolio implication: Avoid longs in these tickers, watch for suspensions amplifying volatility.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 22, 2026

Across 37 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is widespread listing compliance distress, with 10+ companies (e.g., Vivos, Greenwave, Graf, Apimeds, BIO KEY, Tevogen, La Rosa, EON) receiving Nasdaq/NYSE notices for late 10-Ks, negative equity (-$1.55M at Vivos), or market value shortfalls ($50M MVLS/$15M MVPHS at Tevogen), signaling acute financial reporting and balance sheet pressures amid no bankruptcies but high delisting risks. Positive counter-trends include robust financings (e.g., HIVE $100M notes, TuHURA $50M credit, Firefly $8M units, Hepion $700K equity) and M&A/divestitures (Amneal $1.1B biosimilars deal, NHC $560M facilities, Certara $135M sale, Spire $75M divestiture) to extend runways and refocus operations. Period-over-period data shows mixed revenue growth: ServiceNow +22% YoY subscription revenues ($3,671M Q1), Amneal +4% YoY ($723M Q1) with +750bps gross margins to 44.3%, contrasting distress signals; guidance raised at Amneal (Adj EBITDA $740-770M FY26) and ServiceNow (subscription $15.735-15.775B FY26). Capital allocation leans toward debt/equity raises over returns, with ServiceNow repurchasing 20.1M shares. Portfolio-level patterns highlight small-cap biotech/healthcare (Spruce, TuHURA, Hepion) and tech (Greenwave, Tevogen) as distress hotspots, while larger caps like ServiceNow outperform; implications include short-term volatility from compliance deadlines (June-Oct 2026) and alpha in turnaround financings/M&A.

37 high priority 37 total filings
· daily

US Executive Officer Management Changes SEC — April 22, 2026

Across 34 SEC filings on USA Executive & Director Changes dated April 22, 2026, overarching themes include 10 annual shareholder meetings electing directors with mixed support levels (e.g., Equity Bancshares saw 30-40% opposition on some directors, while Seaboard and Citizens Financial passed overwhelmingly), smooth executive successions/retirements (12 cases, neutral sentiment), and strategic appointments in biotech/pharma (7 instances, positive). Period-over-period trends show robust Q1 2026 growth in select firms: Goosehead Insurance revenues +23% YoY to $93.1M, Medpace +26.5% to $706.6M, Kinder Morgan net income +36% YoY to $976M, NB Bancorp net income +95% QoQ to $15M, though offsets like Medpace backlog +2.9% QoQ and NB provision expense swing to $6.3M highlight margin risks. Critical developments: High-materiality CEO transitions at Best Buy (Jason Bonfig effective Oct 31, 2026) and Regal Rexnord (Aamir Paul by Jul 1, 2026) position growth continuity; PubMatic prelim Q1 rev $62.4M beat guidance. Portfolio-level patterns reveal biotech hiring expertise for pipelines (Vanda, Barinthus, Tenax), energy/transport volume declines (Kinder Morgan crude -12% YoY), and capital returns via dividends (Kinder +2%, NB $0.07/share) amid neutral insider conviction from retirements without sales.

33 high priority 1 medium 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 22, 2026

Across 33 filings on USA Board Room Changes (April 22, 2026), dominant themes include orderly executive retirements/resignations (12 cases, e.g., COOs, Presidents, directors) with no disagreements cited, positive CEO successions at majors like Best Buy (Jason Bonfig internal promo effective Oct 31) and Regal Rexnord (Aamir Paul from Schneider effective Jul 1), and board expansions/appointments in biotech/healthcare (9 instances, e.g., Vanda, Tenax, Barinthus CFO). Period-over-period trends show revenue growth in 7/9 financial reporters (avg +23% YoY: Goosehead +23%, Medpace +26.5%, Kinder Morgan net income +36%), but mixed margins/backlogs (Medpace margin -300bps YoY, NB Bancorp provision expense swing); capital allocation bullish with dividends up (Kinder Morgan +2%, NB Bancorp $0.07/share) and buybacks (Goosehead $49.8M). No insider trading patterns, but 5/33 flag strong forward guidance (e.g., Goosehead 10-19% organic growth). Implications: Leadership refreshes signal continuity in growth sectors (biotech, energy), potential alpha in succession plays amid stable financials; watch Q2 catalysts like retirements and earnings for volatility.

33 high priority 33 total filings
· daily

US Merger & Acquisition SEC Filings — April 22, 2026

The 11 filings highlight intense SPAC lifecycle activity in US M&A, with 1 fresh $100M IPO (QuasarEdge), 3 advancing business combinations (Iron Horse $250M+ AI battery deal, Allegro warrant support for SeeQC merger, Constellation HiTech webinar), 4 deadline extensions/postponements (TLGY to July 2026, Pyrophyte trust at $19.5M seeking further extension, SIM EGM delayed to May 1 2026, Everest interest withdrawal amendment), 1 merger termination (Oak Woods), 1 Nasdaq compliance risk (Flag Ship late 10-K), and 1 completed takeover (First Eagle acquires Diamond Hill at $175/share, pro forma AUM $213B). No operational revenue/margin trends available as most are pre-revenue SPACs, but trust account stability is key metric with Pyrophyte at $12.91/share redemption value and full extension deposits made. Positive themes dominate in tech/AI/minerals deals amid prolonged searches, but risks of liquidation/Nasdaq delisting loom for laggards. Portfolio-level pattern: 7/11 filings show extension efforts or new capital (vs 2 failures), implying sector resilience but extended timelines to H2 2026/2027 closings. Market implication: Opportunities in de-SPAC targets like Electra AI battery (backed by Stellantis/Ferrari), while monitor redemptions and compliance.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 22, 2026

Overnight SEC filings reveal a bullish tilt in industrials and healthcare with standout Q1 beats from Vertiv (+30% YoY sales, raised FY guidance), Monarch Casino (record +8.9% revenue, +38.9% net income), and Elevance Health (raised FY EPS to $26.75+ despite CMS accrual hit), contrasting mixed results at Otis Worldwide (+6% sales but -130 bps margins) and ongoing losses at Gaotu Techedu (+35% revenue YoY but net loss $46M). Healthcare shines with National Healthcare's $560M accretive acquisition (Q3 2026 close) and Kyverna's positive KYSA-8 trial data (conference call April 22), while HIVE Digital upsized $100M notes offering for GPU expansion. Capital allocation remains shareholder-friendly: Otis $400M buybacks, Elevance $5.6B repurchase authorization, Monarch $17.6M repurchases + $0.30 dividend. 13F filings (22 total) show institutional stability in ETFs/tech giants (e.g., NVDA, Apple across multiple managers), no major shifts. SPAC activity mixed: Oak Woods merger termination bearish, Archimedes/Forge Nano merger announced. Portfolio-level: 5/7 earnings reporters grew revenue >6% YoY (avg +18%), but margins compressed in 2/5 (-130 to -240 bps); watch guidance catalysts pre-market.

11 high priority 39 medium 50 total filings
· daily

New Federal Contractors — April 21, 2026

The single contract analyzed totals $117,329,394 in obligations, entirely civilian (0/1 defense-related) from the General Services Administration (GSA). PRKK LLC, a small business in Stuart, FL, secured this cost-plus-fixed-fee delivery order for engineering services (NAICS 541330) via full and open competition, with performance ongoing until May 2026 and options to 2027. The neutral signal (4/10 strength) reflects early-stage execution with $0 outlays to date, representing potential GSA civilian engineering support growth. Highest-conviction signal is monitoring outlay progress and option exercises for revenue realization. Key watch item: zero outlays indicate execution risk ahead of the 2026 performance end date.

1 total filings
· daily

Significant Contract Modifications ($10M+) — April 21, 2026

GSA awarded PRKK LLC a single $117,329,394 obligation delivery order for engineering services under a cost-plus fixed fee structure, representing 100% civilian agency spending with zero defense exposure. This neutral signal (avg strength 4/10) stems from a 2022 full and open competition win by the small business, but carries early-stage uncertainty with $0 outlays to date despite a potential value of $154M including options. Dominant theme is civilian GSA allocation to engineering and professional support services (NAICS 541330, PSC R499) in Annapolis, MD. Highest-conviction signal is low execution risk from cost-plus pricing, but key watch item is total outlay progress and option exercises ahead of the 2026-05-24 performance end date.

1 total filings
· daily

Contract Deobligations Alert — April 21, 2026

This Contract Deobligations Alert features a single event where the General Services Administration (GSA) deobligated the full $117,329,394 total obligation from PRKK LLC's engineering services delivery order. The activity is 100% civilian (0/1 defense-related), centered on GSA Federal Acquisition Service spending in professional engineering support (NAICS 541330, PSC R499). The dominant theme is early-stage civilian contract wind-down with zero outlays despite a performance period through 2026-05-24. Highest-conviction signal is neutral (strength 4/10, materiality 3/10), indicating limited broader market impact for the small business recipient. Key watch item is total outlayed progress and option exercise status amid the deobligation.

1 total filings
· daily

Contract Option Exercises — April 21, 2026

This digest covers one contract option exercise totaling $117,329,394 in obligations, entirely civilian with zero defense-related awards from the General Services Administration (GSA). PRKK LLC, a small business, secured a $117M delivery order for engineering services (NAICS 541330) under cost-plus fixed fee pricing, awarded in 2022 with performance through 2026-05-24 and potential extension to 2027-05-24. The dominant theme is GSA Federal Acquisition Service spending on professional support (PSC R499) via full and open competition. Highest-conviction signal is neutral (4/10 strength, 3/10 materiality) due to zero outlays indicating early-stage execution. Key watch item is outlay progress and option exercises toward the $154M ceiling.

1 total filings
· daily

Federal Professional Services Contracts — April 21, 2026

The analyzed contracts total $117,329,394 in obligations across one award, representing 100% civilian exposure from the General Services Administration (GSA) with zero defense-related activity. PRKK LLC, a small business in Stuart, FL, secured this full and open competition delivery order for engineering services (NAICS 541330) and professional support (PSC R499) under cost-plus-fixed-fee pricing, valued at up to $154,764,846 with options. The neutral signal (strength 4/10, materiality 3/10) stems from early-stage execution with $0 outlays despite the significant $117M obligation awarded in 2022. The dominant theme is GSA civilian spending on engineering services in Annapolis, MD. Highest-conviction signal is the competitive win signaling potential revenue of $29.3M annually for PRKK LLC over the current 4-year period. Key watch item is total outlay progress and option exercises ahead of the 2026-05-24 performance end date.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 21, 2026

GSA awarded PRKK LLC a single $117,329,394 mega delivery order for engineering services, representing 100% civilian spending with zero defense-related contracts in the period. This cost-plus fixed fee contract under full and open competition underscores GSA Federal Acquisition Service's allocation to small business providers in professional support (PSC R499). The neutral signal (4/10 strength, 3/10 materiality) reflects a competitive win but early-stage execution with $0 outlays to date. Highest-conviction signal is PRKK LLC's securement of this $117M obligation with low pricing risk and upside to $154M via options. Key watch item is total outlayed progress and option exercises, given the 2026-05-24 performance end date.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 21, 2026

A single high-value federal grant obligated $117,329,394 exclusively to civilian agency spending by the General Services Administration (GSA), with zero defense-related contracts in the period. PRKK LLC, a small business in Stuart, FL, secured this cost-plus fixed fee delivery order for engineering services (NAICS 541330) under full and open competition, valued potentially up to $154,764,846 with options, with performance ongoing through May 2026 in Annapolis, MD. The dominant sector theme is GSA's allocation to professional engineering support (PSC R499), carrying a neutral investment signal of low strength (4/10) and materiality (3/10). Highest-conviction signal is the competitive win for PRKK LLC as a notable early-stage revenue opportunity estimated at $29.3M annually over the current four-year period. Key risk is zero outlays to date, signaling execution uncertainty; watch total outlay progress and option exercises.

1 total filings